Sunshine Heart Hires Gordon Weber as Vice President, General Counsel

EDEN PRAIRIE, Minn., May 16, 2017 -- Sunshine Heart, Inc. (Nasdaq:SSH) announced today that Gordon Weber has accepted the role of Vice President, General Counsel effective May 15, 2017. In his capacity, Mr. Weber will provide legal counsel to the Company and will oversee the Company’s compliance programs as it grows its commercial operations and develops new business opportunities.

“We are thrilled to have someone with Gordon’s caliber and background join the company as our General Counsel,” said John Erb, Chairman and Chief Executive Officer of Sunshine Heart. “His extensive experience working with both established and emerging growth companies will be critical to successfully scale our commercial organization.”

Prior to joining Sunshine Heart, Mr. Weber was Vice President, General Counsel and Corporate Secretary for Vascular Solutions, Inc., a publicly held medical device company, was Associate General Counsel at Smiths Medical, a $1.1B medical device manufacturer, and was a partner at Faegre & Benson LLP.  Mr. Weber holds a J.D. from William Mitchell College of Law, and a B.A. in Accounting and Economics from Luther College.

About Sunshine Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow® System. The Company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Our objective is to improve the quality of life for patients with heart failure and related conditions. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements
Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, our ability to execute on our recently announced strategic realignment, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses. The risk factors described in our filings with the SEC could cause actual events to adversely differ from the expectations indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sunshine Heart does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Sunshine Heart may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our therapy, the possibility we may be unable to raise the funds necessary for the development and commercialization of our therapy and other risks and uncertainties described in our filings with the SEC. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.                             

For further information, please contact: 

Claudia Napal Drayton	
Chief Financial Officer	
Sunshine Heart, Inc.	
T: +1-952-345-4205	

Investor Relations
Sunshine Heart Inc.
[email protected]